Clinical ScienceDescemet Membrane Endothelial Keratoplasty in Congenital Hereditary Endothelial Dystrophy: Initial ExperiencesMittal, Vikas MS; Sehdev, Nancy DNB; Mittal, Ruchi MSAuthor Information Cornea and Ocular Surface Services, LJ Eye Institute, Ambala City, India. Correspondence: Vikas Mittal, MS, Cornea and Ocular Surface Services, LJ Eye Institute, Model Town, Ambala City, Haryana 134002, India (e-mail: [email protected]). The authors have no funding or conflicts of interest to disclose. Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (www.corneajrnl.com). Cornea: August 2021 - Volume 40 - Issue 8 - p 972-976 doi: 10.1097/ICO.0000000000002701 Buy SDC Metrics Abstract Purpose: To report our early experiences with Descemet membrane endothelial keratoplasty (DMEK) in congenital hereditary endothelial dystrophy (CHED). Methods: Retrospective analysis of medical records of eyes with CHED that underwent DMEK between January 1, 2018, and April 30, 2019, and had a minimum of 1-year follow-up. Results: Three eyes of 2 CHED patients (a 10-year-old girl and a 22-year-old man) were included. Both had decreased vision and hazy corneas from birth and underwent DMEK during the study period. Surgery was performed by a single surgeon and was uneventful in all 3 eyes. Within 1 month of surgery, the corneal edema cleared, and vision improved significantly. The mean decimal visual acuity improved from 0.15 ± 0.08 (baseline) to 0.33 ± 0.19 at 3 months. The mean central corneal thickness improved from 928 ± 2.3 μm (baseline) to 555.3 ± 25.8 μm at 3 months. The final visual outcome was less in 1 eye because of dense amblyopia. In all 3 eyes, a subtle stromal haze persisted even after resolution of edema. One eye had graft rejection 7 months after surgery because of discontinuation of medications, effectively managed by increasing the frequency of topical steroids. Conclusions: DMEK may be a viable option in phakic eyes with CHED. Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.